

# ACRUX

**A SPECIALTY PHARMACEUTICAL COMPANY  
WITH PRODUCTS IN LATE STAGE DEVELOPMENT  
FOR LARGE GLOBAL MARKETS**

**April 2006**

# ACRUX'S DRUG DELIVERY TECHNOLOGY




## MDTS® Applicator

Used for simple, accurate & flexible dosing

US Pat. no. 6,978,945

(expires 2022)



## Patchless Patch® Reservoir

Forms an invisible reservoir within the skin

US Pat. no. 6,818,226

(expires 2017)

## ACROSS® Enhancers


Allow drugs to pass through skin more rapidly

US Pat. no. 6,299,900

(expires 2017)

# ACRUX'S COMPETITIVE ADVANTAGES

## Evolution of Passive Transdermal Delivery Systems



	Transdermal Gels	Transdermal Patches	Acrux Technology
No or low risk of skin irritation	✓	✗	✓
Cosmetic acceptability	✗	✗	✓
Dosage flexibility	✗	✗	✓
Ease of manufacture	✗	✗	✓
Cost effective	✓	✗	✓
Range of applications	✗	✓	✓
Preference by patients	✗	✗	✓

# CLEAR PREFERENCE BY PATIENTS

- Market research with 200 women of post-menopause age
  - Patch or implant hormone therapy users – 100% would switch to MDTS®
  - Tablet hormone therapy users – 88% would switch to MDTS®
- Backed up in studies conducted by others



# 40 STAFF & MANAGEMENT IN MELBOURNE



**Igor Gonda, CEO and Managing Director**  
*Former Aradigm (CSO), Genentech*



**Jon Pilcher, Chief Financial Officer**  
*Former ANZ Bank, Celltech, Medeva*



**Adam Watkinson, Chief Scientific Officer**  
*Former ProStrakan*



**Geoff Bolland, Director of Strategic Alliances**  
*Former Cardinal Health*



**Peter Willcocks, Director of Business Development & General Counsel**  
*Former Lander & Rogers, Rigby Cooke*

- Considerable international experience
- Proven commercialisation expertise
- Extensive experience at large pharma companies

# APPENDIX

## SCIENTIFIC ADVISORY BOARD - WORLD CLASS IN TRANSDERMAL DELIVERY & CLINICAL APPLICATIONS

### **Professor Barrie Finnin** (*Chairman*)

#### **Professor Tsuneji Nagai** (*Hoshi University*)

- 3 ethical drugs (Aftach®, Rhinocort®, Salcort®)
- Chairman of Nagai Foundation and former government advisor
- Over 1000 articles/papers

#### **Professor William Charman** (*Monash University*)

- Non Executive Director of Sigma (ASX: SIG)
- Director for Centre for Drug Candidate Optimisation of Monash Uni
- Over 300 papers/communications

#### **Professor Jonathan Hadgraft** (*University of London*)

- Consulting roles for GlaxoSmithKline, Pfizer, Mylan, Pierre Fabre, Molecular Skin Care, Wyeth
- Over 400 articles in dermal drug delivery

#### **Professor Howard Maibach** (*UC San Francisco*)

- Regarded as one of world's leading dermatologists
- 40 books and over 1,500 research papers

#### **Professor Michael Cousins** (*University of Sydney*)

- Member of Order of Australia for contributions to anaesthesia/pain management
- Over 200 research publications

#### **Professor Alastair MacLennan** (*University of Adelaide*)

- Novo Nordisk Award for achievement in field of menopause
- Over 250 research publications


#### **Professor Richard Guy** (*University of Bath*)

- APV Award for outstanding achievement in the pharmaceutical sciences
- Co-edited 7 books, 70 book chapters and more than 200 research articles

# EFFICIENT USE OF CAPITAL

<i>(A\$m unless noted)</i>	Aug 1999	May 2001	Jun 2002	Sep 2004 (IPO)
<b>Capital raised</b>	<b>5.0</b>	<b>11.3</b>	<b>9.8</b>	<b>30.0</b>
Source	Retail	Institutions/Retail	Institution	Institutions/Retail
Lead Manager	TSL	TSL	TSL	Goldman Sachs JBWere
<b>Cumulative cash flow</b>	<b>(0.2)</b>	<b>(3.7)</b>	<b>(6.8)</b>	<b>(19.4)</b>
Key milestones	<ul style="list-style-type: none"> <li>• 1 human study</li> <li>• AU, NZ patent</li> <li>• START grant, A\$3.8m</li> </ul>	<ul style="list-style-type: none"> <li>• 2 human studies</li> <li>• US patent</li> <li>• Pre-IND meeting Estradiol</li> </ul>	<ul style="list-style-type: none"> <li>• 7 human studies with 3 drugs</li> <li>• PHARMACIA, R&amp;D Agreement</li> <li>• US IND Estradiol</li> </ul>	<ul style="list-style-type: none"> <li>• 14 human studies with 6 drugs</li> <li>• Vet products licensed to Eli Lilly</li> <li>• Nestorone JDA with the Population Council</li> <li>• Testosterone Phase 2b running, deal with VIVUS</li> <li>• Estradiol Phase 2 completed, deal with VIVUS</li> <li>• P3 grant, A\$4.2m</li> <li>• CSL deal</li> </ul>

# BROAD AND ROBUST CLINICAL PIPELINE



Registration

*Plus several products in new therapeutic areas prepared for clinical trials...*

